Johnson & Johnson (JNJ -0.3%) Janssen unit has filed a lawsuit in a New Jersey court attempting to block the entry of a biosimilar to top seller Remicade (infliximab) made by Samsung Bioepis, the joint venture between Samsung BioLogics and Biogen (BIIB +0.2%).

Janssen accuses Bioepis of violating Remicade patents and refusing to participate in a patent resolution process for biosimilars. It seeks to block the U.S. market launch of the product, to be marketed by Merck (MRK-0.1%) after last month's FDA approval, in addition to damages.

READ FULL ARTICLE HERE